Virtus LifeSci Biotech Products ETF
0
Funds holding %
of 7,299 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
16% more capital invested
Capital invested by funds: $4.74M [Q4 2024] → $5.49M (+$753K) [Q1 2025]
4.21% more ownership
Funds ownership: 22.56% [Q4 2024] → 26.77% (+4.21%) [Q1 2025]
0% more funds holding
Funds holding: 12 [Q4 2024] → 12 (+0) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Research analyst outlook
We haven’t received any recent analyst ratings for BBP.
Financial journalist opinion
Neutral
Seeking Alpha
2 weeks ago
Healthcare Sector Checkup As U.S. Looks To Change Regulations
Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.
Neutral
Seeking Alpha
3 months ago
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?
Positive
Zacks Investment Research
11 months ago
4 Best-Performing Sector ETFs of June
We have highlighted four top-performing ETFs from different sectors that have led the way in June.
Positive
Zacks Investment Research
1 year ago
Biotech ETFs Stage Solid Comeback at the Start of 2024
The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.
Charts implemented using Lightweight Charts™